Spencer Pharmaceutical Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPPH research report →
Companywww.spencerpharmaceutical.com
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications.
- CEO
- Maximilien Arella
- IPO
- 2023
- Employees
- 2
- HQ
- Boston, US
Price Chart
Valuation
- Market Cap
- $29.44K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -50.17%
- ROIC
- 21.49%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-862,541 · 61.49%
- EPS
- $-1.00 · 66.67%
- Op Income
- $862.54K
- FCF YoY
- 71.26%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.69
- Avg Volume
- 1.01K
Get TickerSpark's AI analysis on SPPH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SPPH Coverage
We haven't published any research on SPPH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SPPH Report →